Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces that it has applied for a voluntary delisting of its Class B subordinate voting shares (“ Class B Shares ”) from the Canadian Securities Exchange (the “ CSE ”). The delisting from the CSE will not affect the Company’s listing on the Nasdaq Capital Market (“ Nasdaq ”), the Frankfurt Stock Exchange or Upstream and its Class B Shares will continue trading on the NASDAQ under the symbol “QNTM”.

The Company believes that the trading volume of its Class B Shares on the CSE no longer justifies the expenses, administrative efforts, and regulatory burdens associated with maintaining a dual listing. The Company also believes that delisting from the CSE will consolidate trading of its Class B Shares into a single principal marketplace on Nasdaq, which the Company expects may benefit the long-term liquidity of the Class B Shares.

A welcome email is on its way. If you don't see it, please check your junk folder.

The Company will remain a reporting issuer in each of the Canadian jurisdictions in which it is currently a reporting issuer and will continue to file its continuous disclosure documents on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Shareholders who hold Class B Shares through a Canadian broker are not required to take any action as a result of the delisting; however, shareholders should contact their broker or other intermediary to confirm that their account permits trading on Nasdaq and to discuss any resulting settlement, currency conversion or commission considerations.

The Company is grateful to the CSE for providing its initial opportunity to access public markets. It is expected, subject to approval from the CSE, that the close of business on Friday, September 4, 2026, will be the last trading day for the Class B Shares on the CSE.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc.